Patients saw improved event-free survival and overall survival with presurgical Imfinzi and chemotherapy followed by surgery and postsurgical Imfinzi. Treatment with Imfinzi (durvalumab) before and ...
Zacks Investment Research on MSN
NTRA's Signatera CDx wins FDA nod in muscle-invasive bladder cancer
Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant ...
A real-world US community-based evaluation of recurrence among non-muscle-invasive bladder cancer patients treated with bacillus Calmette-Guérin. Description and management strategies of prespecified ...
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer ...
ImmunityBio Inc. IBRX stock is up during Wednesday’s premarket session as the company is gaining attention following the ...
The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with ...
Securing Medicare coverage and launching our first TrueMRD Test are significant milestones for Veracyte and important steps in enabling access to our MRD testing platform,” said Marc Stapley, Veracyte ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results